Previous 10 | Next 10 |
home / stock / mrk / mrk articles
In the current session, the stock is trading at $103.50, after a 0.78% increase. Over the past month, Merck & Co Inc. (NYSE:MRK) stock increase...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Corning Incorporated (NYSE: GLW) reported a disappointing quarter. "I...
The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...
Merck & Company, Inc. (NYSE: MRK) Q3 sales reached $15.962 billion, up 7% Y/Y, beating the consensus of $15.320 billion, reflecting s...
A somber mood looms over Wall Street, stirred by lackluster earnings reports and relentless bond yield increases. Stock futures dipped early Thursd...
After the first week of earnings, analysts have tempered their expectations for profit growth, anticipating a continuation of the profit-decli...
Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global developme...
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small ...
Merck & Co Inc (NYSE: MRK) reported topline data from the Phase 3 KEYNOTE-671 trial investigating Keytruda, Merck's anti-PD-1 therapy,...
News, Short Squeeze, Breakout and More Instantly...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the fourth quarter of 2024. Payment will be made on Oct. 7, 2024, to shareholders of r...
2024-07-23 09:30:00 ET The Dow Jones Industrial Average has long been a bellwether for the overall health of the U.S. stock market, tracking 30 large publicly owned companies across various sectors. While the index has seen modest gains in 2024, one of its constituents has been signific...
Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), the company’s investigati...